Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: Clobenpropit dihydrobromide is a selective histamine H3 receptor antagonist that crosses the blood-brain barrier; inhibits histamine binding in rat brain with an ED50 value of 10.5 mg/kg; protects cultured cortical neurons from NMDA-induced excitotoxicity by stimulating GABA release; in mice and rats protects against kindled seizures through its effects on histamine and GABA.
Clobenpropit (dihydrobromide) is supplied as a crystalline solid. A stock solution may be made by dissolving the clobenpropit (dihydrobromide) in an organic solvent purged with an inert gas. Clobenpropit (dihydrobromide) is soluble in organic solvents such as ethanol and DMSO. The solubility of clobenpropit (dihydrobromide) in ethanol and DMSO is approximately 2.5 and 30 mg/ml, respectively. Organic solvent-free aqueous solutions of clobenpropit (dihydrobromide) can be prepared by directly dissolving the crystalline compound in water. The solubility of clobenpropit (dihydrobromide) in water, is approximately 20 mg/ml. We do not recommend storing the aqueous solution for more than one day.
Barnes, J.C., Brown, J.D., Clarke, N.P., et al. Pharmacological activity of VUF 9153, an isothiourea histamine H3 receptor antagonist. Eur. J. Pharmacol. 250, 147-152 (1993).
Dai, H., Fu, Q., Shen, Y., et al. The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons. Eur. J. Pharmacol. 563, 117-123 (2007).
Harada, C., Fujii, Y., Hirai, T., et al. Inhibitory effect of iodophenprofit, a selective histamine H3 antagonist, on amygdaloid kindled seizures. Brain Res. Bull. 63, 143-146 (2004).